{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001).","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_3","claim":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_4","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_5","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_6","claim":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]}]}